BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Recent advances in the CML treatment suggested around 40 % of patients can achieve treatment free remission without requiring active CML treatment even after stopping TKI in the patients attained deeper molecular response (defined as 4.5 log reduction of bcr-abl1 transcript or deeper) for 2 years or longer following imatinib therapy for 5 years or longer.